A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease
- 11 April 2006
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (5) , 639-644
- https://doi.org/10.1016/j.cgh.2006.02.004
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patientsAlimentary Pharmacology & Therapeutics, 2004
- Pharmacotherapy of ObesityAmerican Journal of Cardiovascular Drugs, 2002
- Plasma Fatty Acids, Adiposity, and Variance of Skeletal Muscle Insulin Resistance in Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2001
- Loss of Insulin Signaling in Hepatocytes Leads to Severe Insulin Resistance and Progressive Hepatic DysfunctionPublished by Elsevier ,2000
- Loss of Insulin Signaling in Hepatocytes Leads to Severe Insulin Resistance and Progressive Hepatic DysfunctionMolecular Cell, 2000
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Nonalcoholic SteatohepatitisSeminars in Liver Disease, 1999
- Ursodeoxycholic Acid or Clofibrate in the Treatment of Non–Alcohol–Induced Steatohepatitis: A Pilot StudyHepatology, 1996
- Hepatic effects of dietary weight loss in morbidly obese subjectsJournal of Hepatology, 1991
- Ultrasound scanning in the detection of hepatic fibrosis and steatosis.BMJ, 1986